Videos

Drs Tannir, Tykodi, and Ornstein debate whether single-agent TKI therapies still have a place in advanced clear cell RCC treatment, especially for favorable-risk patients.

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.

Paul A. DiSilvestro discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial.

Ruben Mesa, MD, discusses crucial data from the COMFORT studies that show ruxolitinib's benefit in patients with myelofibrosis.

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Moshe Ornstein, MD, MA, explains the factors he considers when deciding on a combination treatment regimen for a patient with favorable-risk advanced clear cell RCC.

An expert presents the case of a 68-year-old woman with favorable-risk advanced clear cell RCC for discussion.

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Srdan Verstovsek, MD, PhD, discusses why the first ever FDA approved interferon drug ropeginterferon alfa-2b-njft is important for adult patients with polycythemia vera.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.

Karen L. Reckamp, MD, discusses the key findings of the phase 2 Lung-MAP substudy S1800A for patients with stage IV, previously-treated non–small cell lung cancer.

Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.

Insight on recent developments and emerging options in the mCSPC treatment landscape.

An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.

Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.

Christopher J. Melani, MD, discusses the results of a trial investigating a combination regimen in a cohort of patients with mantle cell lymphoma.

Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.

A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.

Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.

Jeffrey Miller, MD, discusses what is next to come following an analysis of GTB-3550.

William J. Gradishar, MD, discusses the most recent evolutions in the management of patients with advanced breast cancer.

Dr Nizar Tannir compares data among the 4 approved first-line I/O combination therapy regimens in advanced clear cell RCC.

Nizar Tannir, MD, provides an overview of the method of risk stratification for advanced RCC and the NCCN Guidelines for treatment based on risk group.